Press Releases

EpicentRx Announces Presentation for Phase 2 Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 vs. regorafenib in Third/Fourth Line Colorectal Cancer at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal...

Results from PREVLAR trial Demonstrate RRx-001 protects against severe oral mucositis or blistering from radiation in first line head and neck cancer Study published in International Journal of Radiation Oncology, Biology and Physics, also known as The Red Journal...

Results from the ROCKET trial, published in the journal Clinical Colorectal Cancer, demonstrate the potential chemoprotective effects of RRx-001 San Diego, Calif., Dec. 14, 2022 - EpicentRx Inc. (“EpicentRx”), a leading-edge, clinical stage biopharmaceutical company...

Dual anti-cancer and radio/chemoprotective agent reduces toxicity from radiation exposure Torrey Pines, Calif., December 6, 2022 - EpicentRx Inc. (“EpicentRx”), a leading-edge, clinical stage biopharmaceutical company that uses groundbreaking science to treat cancer...

The funding will support study of lead small molecule inflammasome inhibitor in MND, also known as amyotrophic lateral sclerosis (ALS) Torrey Pines, Calif. and Queensland, Australia, Nov. 29, 2022 /PRNewswire/ - EpicentRx Inc. ("EpicentRx"), a late-stage...

Presentations at Neuroscience 2022 and the 4th Inflammasome Therapeutics Summit will highlight the potential for RRx-001 to prevent and treat a broad range of chronic diseases Torrey Pines, Calif., November 10, 2022 – EpicentRx, a late clinical stage biopharmaceutical...

License partner SciClone Pharmaceuticals oversees trial in China. Phase 3 REPLATINUM multicenter clinical trial with over 50 sites in the U.S. and China is underway Torrey Pines, Calif., Oct. 6, 2022 /PRNewswire/ - EpicentRx, a late clinical stage biopharmaceutical...

Commentary points to need for a vaccine based on nucleocapsid vs. spike protein to make vaccine less vulnerable to mutation and provide stronger immunity to novel viral variants Company’s development of a nucleocapsid vaccine, a recombinant replication-competent...

BRISBANE, AUSTRALIA, July 12, 2022 – University of Queensland researchers will partner with American biopharmaceutical company EpicentRx Inc. to evaluate new treatments for Parkinson’s disease (PD), speeding up development of potential new therapies. UQ and EpicentRx...

The $500,000 USD grant will support study of EpicentRx’s lead small molecule inflammasome inhibitor TORREY PINES, Calif., July 12, 2022 -- EpicentRx Inc. (“EpicentRx”), a late-stage biopharmaceutical company developing platforms that treat and target multiple...

TORREY PINES, Calif., June 1, 2022 -- EpicentRx, Inc, a privately-held clinical-stage biotechnology company at the forefront of developing oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that...

TORREY PINES, Calif., May 10, 2022 -- EpicentRx, Inc., a privately-held clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that it has been...

Phase 1 trial with cancer-targeting adenovirus enhanced with a TGFβ Trap continues to investigate safety and anti-tumor activity in patients with advanced cancer TORREY PINES, Calif., April 21, 2022 -- EpicentRx Inc., a leading-edge immunotherapy company using...

TORREY PINES, Calif., Feb. 23, 2022 – EpicentRx, Inc., a clinical stage drug and device company, in collaboration with the Texas Children's Cancer Center in Houston, today announced the start of a Phase 1 study to examine the safety and benefit of its lead small...

Collaboration builds on recent data presented by Actinium at SITC demonstrating enhanced activity of targeted radiotherapies in combination with the anti-CD47 targeting antibody magrolimab in blood cancer and solid tumor models Collaboration to explore Actinium’s...

Oncolytic Adenovirus in Phase 1 has extended half-life TGF-ß trap La Jolla, Calif., Dec. 8, 2021 - EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other...

La Jolla, Calif., Nov. 22, 2021 - EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and...

MOUNTAIN VIEW, Calif., August 19, 2015 -- EpicentRx, Inc., a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of potent, novel anti-cancer agents, announced today the publication of positive results...

Cancer-targeting adenovirus enhanced with a TGFβ Trap well tolerated in patients with advanced cancer Torrey Pines, Calif., Sept. 29, 2021- EpicentRx Inc., a leading-edge drug and device company with cancer and inflammatory disease-targeted platforms, today announced...

Company secures 10M US dollar growth capital term loan from Silicon Valley Bank (SVB) to accelerate development of immunotherapies for cancer AdAPT-001, a TGF-beta trap expressing oncolytic virus, designed to activate the immune system and improve checkpoint...

SciClone granted exclusive license to co-develop and commercialize RRx-001 upon approval in the Greater China Region LA JOLLA, Calif., July 1, 2020 -- EpicentRx Inc. ("EpicentRx"), a San Diego-based clinical cancer immunotherapy company and SciClone Pharmaceuticals...

TORREY PINES, Calif., June 10, 2020 -- EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need such...

TORREY PINES, Calif., May 29, 2020 -- EpicentRx, a next-generation clinical immuno-oncology company, today announced the appointment of physician, scientist and businessman Tony Reid, M.D., Ph.D., as the company's chief executive officer. Dr. Reid who is a co-founder...

EpicentRx’s lead program is the first-in-class small molecule CD47 antagonist RRx-001 in Phase 3 for small cell lung cancer Enrollment of Phase I trial for adenovirus program AIM-001 expected to begin this year Close of recent $35M series D will advance AIM-001 and...

TORREY PINES, Calif., June 10, 2020 -- EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need such...

RRx-001 led to an overall survival of 21.9 months and progression-free survival of 13 months Data presented at the Society for Neuro-Oncology annual meeting LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune...

Series D Funded by an undisclosed source from Europe Total capital raised by EpicentRx approximately $77 million LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with...

LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has dosed the first patient in the Phase 3 REPLATINUM trial evaluating...

LA JOLLA, Calif., June 25, 2019 -- EpicentRx Inc., a clinical-stage immuno-oncology company with two platforms developed to prime and activate both innate and adaptive anticancer responses, today announced the publication of positive results from its Phase 2 clinical...